Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false2024-02-01falseResearch and experimental development on biotechnology65true 13146056 2024-02-01 2024-12-31 13146056 2023-02-01 2024-01-31 13146056 2024-12-31 13146056 2024-01-31 13146056 c:Director2 2024-02-01 2024-12-31 13146056 d:PlantMachinery 2024-02-01 2024-12-31 13146056 d:PlantMachinery 2024-12-31 13146056 d:PlantMachinery 2024-01-31 13146056 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-02-01 2024-12-31 13146056 d:OfficeEquipment 2024-02-01 2024-12-31 13146056 d:OfficeEquipment 2024-12-31 13146056 d:OfficeEquipment 2024-01-31 13146056 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-02-01 2024-12-31 13146056 d:OwnedOrFreeholdAssets 2024-02-01 2024-12-31 13146056 d:CurrentFinancialInstruments 2024-12-31 13146056 d:CurrentFinancialInstruments 2024-01-31 13146056 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 13146056 d:CurrentFinancialInstruments d:WithinOneYear 2024-01-31 13146056 d:ShareCapital 2024-12-31 13146056 d:ShareCapital 2024-01-31 13146056 d:SharePremium 2024-12-31 13146056 d:SharePremium 2024-01-31 13146056 d:RetainedEarningsAccumulatedLosses 2024-12-31 13146056 d:RetainedEarningsAccumulatedLosses 2024-01-31 13146056 c:OrdinaryShareClass1 2024-02-01 2024-12-31 13146056 c:OrdinaryShareClass1 2024-12-31 13146056 c:OrdinaryShareClass1 2024-01-31 13146056 c:FRS102 2024-02-01 2024-12-31 13146056 c:AuditExempt-NoAccountantsReport 2024-02-01 2024-12-31 13146056 c:FullAccounts 2024-02-01 2024-12-31 13146056 c:PrivateLimitedCompanyLtd 2024-02-01 2024-12-31 13146056 d:WithinOneYear 2024-12-31 13146056 d:WithinOneYear 2024-01-31 13146056 d:BetweenOneFiveYears 2024-12-31 13146056 d:BetweenOneFiveYears 2024-01-31 13146056 e:PoundSterling 2024-02-01 2024-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 13146056









NEOBE THERAPEUTICS LTD







UNAUDITED

FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2024

 
NEOBE THERAPEUTICS LTD
REGISTERED NUMBER: 13146056

BALANCE SHEET
AS AT 31 DECEMBER 2024

Period ended 31 December 2024
Year ended 31 January 2024
Note
£
£

FIXED ASSETS
  

Tangible assets
 4 
8,673
6,834

  
8,673
6,834

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
381,563
137,043

Cash at bank and in hand
  
440,326
1,037,336

  
821,889
1,174,379

Creditors: amounts falling due within one year
 6 
(137,061)
(50,493)

NET CURRENT ASSETS
  
 
 
684,828
 
 
1,123,886

TOTAL ASSETS LESS CURRENT LIABILITIES
  
693,501
1,130,720

  

NET ASSETS
  
693,501
1,130,720


CAPITAL AND RESERVES
  

Called up share capital 
 7 
181
181

Share premium account
  
1,520,347
1,520,347

Profit and loss account
  
(827,027)
(389,808)

  
693,501
1,130,720


Page 1

 
NEOBE THERAPEUTICS LTD
REGISTERED NUMBER: 13146056
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the Period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Dr P Correa de Sampaio
Director

Date: 26 August 2025

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
NEOBE THERAPEUTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

1.


GENERAL INFORMATION

Neobe Therapeutics Limited is a private company limited by shares and is incorporated in England and Wales. The registered office address is Salisbury House, Station Road, Cambridge, CB1 2LA. 
The functional and presentational currency is GBP. 

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

The financial statements have been prepared on the going concern basis which assumes that the Company will continue as a going concern for the foreseeable future. The trading losses reported to date are consistent with the Company's buinsess plan as it progresses its research and development activities.
Given the investment received, together with the development progress achieved, the directors have a reasonable expecation that the Company will be able to meet its liabilites as they fall due for the foreseeable future and therefore continue to adopt the going concern basis. 

 
2.3

RESEARCH AND DEVELOPMENT

Research and development expenditure is recognised in the Profit and Loss Account in the period in which the expenditure was incurred.

 
2.4

GOVERNMENT GRANTS

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Profit and Loss Account in the same period as the related expenditure.

Page 3

 
NEOBE THERAPEUTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.5

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.6

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
25%
straight-line
Office equipment
-
25%
straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
NEOBE THERAPEUTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

3.


EMPLOYEES

The average monthly number of employees, including directors, during the Period was 6 (2024 - 5).


4.


TANGIBLE FIXED ASSETS







Plant and machinery
Office equipment
Total

£
£
£



COST OR VALUATION


At 1 February 2024
6,838
412
7,250


Additions
3,168
718
3,886



At 31 December 2024

10,006
1,130
11,136



DEPRECIATION


At 1 February 2024
330
86
416


Charge for the Period on owned assets
1,828
219
2,047



At 31 December 2024

2,158
305
2,463



NET BOOK VALUE



At 31 December 2024
7,848
825
8,673



At 31 January 2024
6,508
326
6,834

Page 5

 
NEOBE THERAPEUTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

5.


DEBTORS

Period ended 31 December 2024
Year ended 31 January 2024
£
£


Other debtors
189,792
60,355

Prepayments and accrued income
191,771
76,688

381,563
137,043



6.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Period ended 31 December 2024
Year ended 31 January 2024
£
£

Trade creditors
120,682
40,803

Other taxation and social security
11,970
6,917

Other creditors
1,559
1,079

Accruals and deferred income
2,850
1,694

137,061
50,493


Included within other creditors are amount due to the defined contribution pension scheme of £1,559 (2024: £1,079).


7.


SHARE CAPITAL

Period ended 31 December 2024
Year ended 31 January 2024
£
£
ALLOTTED, CALLED UP AND FULLY PAID



180,611 (2024 - 120,858) Ordinary shares of £0.001 each
181
181


Page 6

 
NEOBE THERAPEUTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

8.


COMMITMENTS UNDER OPERATING LEASES

At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

Period ended 31 December 2024
Year ended 31 January 2024
£
£


Not later than 1 year
31,686
17,419

Later than 1 year and not later than 5 years
8,395
2,903

40,081
20,322

 
Page 7